Carl Mitchell, MD
Internal Medicine · Columbia, SCNPI 1932192044
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.5% of the total across 110 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 16 manufacturers reported payments, led by AstraZeneca at 36.7% of the total. Reporting peaked in 2019 at $543 and has fallen 82.1% since, to $97 in 2024.
Across 110 payments — averaging $17.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$725
- Novo Nordisk$295
- Lilly USA, LLC$207
- Merck$151
- Abbott$111
- AbbVie$107
- plus $382 from 10 others
Across 38 payments — averaging $14,790 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sanofi US Services Inc.$562K
What the payments were for
- Food & beverage$1,94898%
- Education$302%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 34 | $725 |
| Novo Nordisk | 17 | $295 |
| Lilly USA, LLC | 13 | $207 |
| Merck | 11 | $151 |
| Abbott | 6 | $111 |
| AbbVie(2 entities) | 6 | $107 |
| Sanofi-aventis U.S. LLC | 4 | $71 |
| Hikma Pharmaceuticals USA | 5 | $66 |
| Alnylam Pharmaceuticals Inc. | 3 | $62 |
| Amgen | 3 | $52 |
| Boehringer Ingelheim | 2 | $37 |
| Bayer | 2 | $29 |
| Eisai Inc. | 1 | $23 |
| Kowa Pharmaceuticals America, Inc. | 1 | $16 |
| Renalytix AI, Inc. | 1 | $14 |
| GSK | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FARXIGA$125
How this compares
$1,978 in reported general payments places this provider in the 75th percentile of 1,498 internal medicine providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 37 | $47,993 |
| FarxigaDapagliflozin Propanediol | 31 | $36,434 |
| MounjaroTirzepatide | 17 | $28,806 |
| EliquisApixaban | 30 | $24,469 |
| JardianceEmpagliflozin | 23 | $18,036 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 11 | $17,161 |
| JanuviaSitagliptin Phosphate | 19 | $16,392 |
| Tresiba Flextouch U-100Insulin Degludec | 23 | $11,363 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 15 | $2,436 |
| Atorvastatin Calcium | 200 | $2,187 |
| Colchicine | 26 | $2,170 |
| Memantine Hcl | 19 | $1,897 |
| Gabapentin | 107 | $1,790 |
| Losartan Potassium | 154 | $1,683 |
| Novolog Mix 70-30 FlexpenInsulin Aspart Prot/Insuln Asp | 12 | $1,592 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Breztri Aerosphere | $725 | $53,59542 claims |
| Novo NordiskOzempic | $295 | $47,99337 claims |
| Lilly USA, LLCMounjaro | $207 | $28,80617 claims |
| Boehringer IngelheimJardiance | $37 | $18,03623 claims |
| MerckJanuvia | $151 | $16,39219 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,498 internal medicine providers in South Carolina.
Other internal medicine in Columbia
- Meer FakhryColumbia$22K
- Laura LabooneColumbia$16K
- Charles ButlerColumbia$15K
- Adelero AdebajoColumbia$12K
- Robert CollinsColumbia$11K
- Albert HumphreyColumbia$10K
- Elizabeth LebelColumbia$10K
- Jerry BackNorth Charleston$322K
- Jan BasileCharleston$278K
- Mark PurcellGreenville$165K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.